Severe HypertriglyceridemiaPhase 3ENTRUSTNCT05852431
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
A Phase 3 study testing Pegozafermin in people with Severe Hypertriglyceridemia, run by 89bio, Inc. at 177 sites in 20 countries.
Trial summary
To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment. Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Severe Hypertriglyceridemia
- What is being tested?
- Pegozafermin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 369 participants
- Where
- 177 sitesin 20 countries
- Study dates
- 15 Jun 2023to 9 Apr 2026
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥22 years
- Willing to enter a medication/lifestyle stabilization period during the screening period, which means maintaining those stable medication, eating, and exercise habits for the duration of the study
- Subjects should be on stable background Lipid Modifying Therapy (LMT) to manage ASCVD for a minimum of 4 weeks prior to first qualifying TG
Who cannot join
- Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
- Uncontrolled or newly diagnosed (≤3 months since diagnosis) Type 2 diabetes mellitus as determined by the Principal Investigator. Subjects must have HbA1c level ≤9.5% at Screening. Medications for glucose management must be stable for at least 4 weeks prior to Screening
- Type 1 diabetes mellitus
- A history of symptomatic gallstone disease, gallstone pancreatitis (unless treated with cholecystectomy), or any other ongoing symptomatic biliary disease
- Acute pancreatitis within 6 months prior to Screening
- Subjects with chronic pancreatitis
- Known or suspected familial chylomicronemia syndrome (FCS) (Type 1 hyperlipoproteinemia)
- Other inclusion and exclusion criteria may apply.
Trial locations and contacts
177 sites in 20 countries.
177 sites in 20 countries
United States73 sites
89bio Clinical Study Site
Amarillo, Texas, 79106
89bio Clinical Study Site
Atlanta, Georgia, 30309
89 Clinical Study Site
Austin, Texas, 78757
89bio Clinical Study Site
Bridgeport, Connecticut, 06610
89Bio Clinical Study Site
Burke, Virginia, 22015
89bio Clinical Study Site
Chandler, Arizona, 85712
89bio Clinical Study Site
Charleston, South Carolina, 29414
89Bio Clinical Study Site
Chattanooga, Tennessee, 37421
89Bio Clinical Study Site
Chicago, Illinois, 60607
89bio Clinical Study Site
Cincinnati, Ohio, 45227
89bio Clinical Trial Site
Clarksville, Tennessee, 37040
89Bio Clinical Study Site
Clearwater, Florida, 33756
89bio Clinical Study Site
Clearwater, Florida, 33761
89Bio Clinical Study Site
Columbus, Georgia, 31904
89bio Clinical Trial Site
Columbus, Ohio, 43213
89bio Clinical Study Site
Conway, Arkansas, 72032
89bio Clinical Study Site
Dallas, Texas, 75226
89bio Clinical Study Site
East Syracuse, New York, 13057
89Bio Clinical Study Site
Eugene, Oregon, 97404
89bio Clinical Study Site
Flint, Michigan, 48504
89bio Clinical Study Site
Graham, Texas, 76450
89bio Clinical Study Site
Hialeah Gardens, Florida, 33016
89Bio Clinical Study Site
Homestead, Florida, 33030
89bio Clinical Study Site
Houston, Texas, 77030
89bio Clinical Trial Site
Huntington Park, California, 90255
89bio Clinical Study Site
Jonesboro, Arkansas, 72401
89bio Clinical Trial Site
Kansas City, Missouri, 64131
89Bio Clinical Study Site
Lampasas, Texas, 76550
89bio Clinical Study Site
Las Vegas, Nevada, 89106
89bio Clinical Study Site
Las Vegas, Nevada, 89118
89Bio Clinical Study Site
Lawrenceville, Georgia, 30044
89bio Clinical Study Site
Little Rock, Arkansas, 72205
89Bio Clinical Study Site
Long Beach, California, 90815
89bio Clinical Study Site
Los Angeles, California, 90057
89bio Clinical Study Site
Mansfield, Texas, 76063
89Bio Clinical Study Site
Marrero, Louisiana, 70072
89Bio Clinical Study Site
Miami Lakes, Florida, 33014
89bio Clinical Study Site
Middleburg Heights, Ohio, 44130
89bio Clinical Study Site
Miramar, Florida, 33027
89Bio Clinical Study Site
Morganton, North Carolina, 28655
89bio Clinical Trial Site
New Windsor, New York, 12553
89bio Clinical Trial Site
New York, New York, 10029
89Bio Clinical Study Site
North Massapequa, New York, 11758
89bio Clinical Trial Site
Northridge, California, 91325
89bio Clinical Study Site
Oklahoma City, Oklahoma, 73102
89Bio Clinical Study Site
Orlando, Florida, 32825
89Bio Clinical Study Site
Oxon Hill, Maryland, 20745
89bio Clinical Study Site
Panama City, Florida, 32401
89bio Clinical Trial Site
Panorama City, California, 91402
89bio Clinical Study Site
Peoria, Arizona, 85381
89bio Clinical Trial Site
Port Orange, Florida, 32127
89bio Clinical Trial Site
Richmond, Virginia, 23249
89bio Clinical Trial Site
Richmond Hill, New York, 77379
89bio Clinical Trial Site
Salt Lake City, Utah, 84107
89bio Clinical Trial Site
San Antonio, Texas, 78207
89bio Clinical Study Site
San Antonio, Texas, 78209
89bio Clinical Study Site
Santa Ana, California, 92705
89bio Clinical Trial Site
Santa Ana, California, 92705
89bio Clinical Trial Site
Shreveport, Louisiana, 71105
89bio Clinical Study Sites
Sparta, New Jersey, 07871
89bio Clinical Study Site
St Louis, Missouri, 63110
89bio Clinical Study Site
Stow, Ohio, 44224
89bio Clinical Trial Site
Syracuse, New York, 13057
89Bio Clinical Study Site
Tampa, Florida, 33606
89bio Clinical Study Site
Thousand Oaks, California, 91360
89Bio Clinical Study Site
Tucson, Arizona, 85712
89bio Clinical Study Site
Tullahoma, Tennessee, 37388
89Bio Clinical Study Site
Tustin, California, 92780
89bio Clinical Study Site
West Des Moines, Iowa, 50265
89bio Clinical Study Site
Wheat Ridge, Colorado, 80033
89bio Clinical Trial Site
Wheat Ridge, Colorado, 80033
89Bio Clinical Study Site
Wichita, Kansas, 67205
89bio Clinical Study Site
Wichita Falls, Texas, 76301
Argentina13 sites
89bio Clinical Study Site
Buenos Aires, C1023AAB
89bio Clinical Study Site
Buenos Aires, C1425CABA
89bio Clinical Study Site
Buenos Aires, C1426ABP
89bio Clinical Study Site
Córdoba, 5000
89bio Clinical Study Site
Córdoba, 5749
89bio Clinical Study Site
Córdoba, X5000 BSQ
89bio Clinical Study Site
Córdoba, X5000AAX
89bio Clinical Study Site
Córdoba, X5004CDT
89bio Clinical Study Site
Mendoza, M5509
89bio Clinical Study Site
Rosario, Santa Fe Province, 2000
89bio Clinical Study Site
Rosario, S2000CVD
89bio Clinical Study Site
San Miguel de Tucumán, T400IHE
89bio Clinical Study Site
Viedma, R8500ACE
Bulgaria12 sites
89bio Clinical Trial Site
Botevgrad, 2140
89bio Clinical Study Site
Dimitrovgrad, 6400
89bio Clinical Trial Site
Plovdiv, 4004
89bio Clinical Study Site
Sliven, 8800
89bio Clinical Trial Site
Sliven, 8800
89bio Clinical Trial Site
Sofia, 1202
89bio Clinical Study Site
Sofia, 1336
89bio Clinical Study Site
Sofia, 1431
89bio Clinical Study Site
Sofia, 1606
89bio Clinical Study Site
Sofia, 1618
89bio Clinical Study Site
Veliko Tarnovo, 5000
89bio Clinical Trial Site
Veliko Tarnovo, 5000
Spain11 sites
89bio Clinical Study Site
Barcelona, 08036
89bio Clinical Study Site
Barcelona, 08041
89bio Clinical Study Site
Barcelona, 08907
89bio Clinical Study Site
Cadiz, 11009
89bio Clinical Study Site
Córdoba, 14004
89bio Clinical Study Site
Granada, 18014
89bio Clinical Study Site
Granada, 18016
89bio Clinical Study Site
Huelva, 21005
89bio Clinical Study Site
Madrid, 28041
89bio Clinical Study Site
Málaga, 29004
89bio Clinical Study Site
Pamplona, 31008
India7 sites
89bio Clinical Study Site
Belagāve, 590010
89bio Clinical Study Site
Bīkaner, 334001
89bio Clinical Study Site
Dehradun, 248001
89bio Clinical Study Site
Jaipur, 302017
89bio Clinical Study Site
Nagpur, 441108
89bio Clinical Study Site
Pimpri-Chinchwad, 411057
89bio Clinical Study Site
Varanasi, 221010
Poland7 sites
89bio Clinical Study Site
Bialystok, 15-351
89bio Clinical Study Site
Krakow, 30-348
89bio Clinical Study Site
Krakow, 31-501
89bio Clinical Study Site
Lodz, 91-363
89bio Clinical Study Site
Lodz, 93-338
89bio Clinical Study Site
Lublin, 20-362
89bio Clinical Study Site
Warsaw, 00-215
Canada6 sites
89bio Clinical Study Site
Brampton, Ontario, L6R3J7
89bio Clinical Study Site
Chicoutimi, Quebec, G7H 7K9
89bio Clinical Study Site
Laval, Quebec, H7T2P5
89bio Clinical Study Site
Montreal, Quebec, H2W1R7
89bio Clinical Study Site
North Vancouver, British Columbia, V7M 2H4
89bio Clinical Study Site
Québec, Quebec, G1V 4G5
Georgia6 sites
89bio Clinical Study Site
Batumi, 6000
89bio Clinical Trial Site
Kutaisi, 4600
89bio Clinical Trial Site
Tbilisi, 0159
89bio Clinical Study Site
Tbilisi, 0160
89bio Clinical Study Site
Tbilisi, 0177
89bio Clinical Study Site
Tbilisi, 0186
Mexico6 sites
89bio Clinical Study Site
Cuernavaca
89bio Clinical Study Site
General Escobedo, 66050
89bio Clinical Study Site
Guadalajara, 76100
89bio Clinical Study Site
Monterrey, Nuevo León, 64310
89bio Clinical Study Site
Querétaro City, 76100
89bio Clinical Study Site
Tlalpan, 14080
Chile5 sites
89bio Clinical Study Site
Concepción, 4030000
89bio Clinical Study Site
Santiago, 8330336
89bio Clinical Study Site
Santiago, 8910259
89bio Clinical Study Site
Valdivia, 5090000
89bio Clinical Study Site
Viña del Mar, 2520997
Czechia5 sites
89bio Clinical Study Site
Brno, 60200
89bio Clinical Study Site
Brno, 65691
89bio Clinical Study Site
Prague, 12808
89bio Clinical Study Site
Prague, 14021
89bio Clinical Study Site
Prague, 15006
Belgium4 sites
89bio Clinical Study Site
Edegem, 2650
89bio Clinical Study Site
Ghent, 9000
89bio Clinical Study Site
Haine-Saint-Paul, 7100
89bio Clinical Study Site
Yvoir, 5530
Hungary4 sites
89bio Clinical Study Site
Baja
89bio Clinical Trial Site
Balatonfüred, 8230
89bio Clinical Trial Site
Budapest, 1122
89bio Clinical Study Site
Nyíregyháza, 4400
Italy4 sites
89bio Cllinical Study Site
Genova, 16132
89bio Clinical Study Site
Milan, 20138
89bio Clinical Study Site
Modena, 41126
89bio Clinical Study Site
Reggio Emilia, 42123
Austria3 sites
89bio Clinical Study Site
Graz, A-8036
89bio Clinical Trial Site
Vienna, 1030
89bio Clinical Trial Site
Vienna, 1130
France3 sites
89bio Clinical Study Site
Marseille, 13005
89bio Clinical Study Site
Paris, 75013
89bio Clinical Study Site
Valenciennes, 59300
Latvia3 sites
89bio Clinical Study Site
Daugavpils
89bio Clinical Trial Site
Riga, 1002
89bio Clinical Study Site
Zemgale, 1002
Germany2 sites
89bio Clinical Study Site
Essen, 45147
89bio Clinical Study Site
Leipzig, 27 04103
United Kingdom2 sites
89bio Clinical Study Site
Cardiff, CF14 4XW
89bio Clincal Study Site
London, N128BU
About this study
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study
To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.
- Conditions
- Severe Hypertriglyceridemia
- Being tested
- Pegozafermin, Placebo
- Keywords
- SHTG, Hypertriglyceridemia, Metabolic diseases, Hyperlipidemias, Dyslipidemias, Lipid Metabolism Disorders
- Medical subject headings
- Hypertriglyceridemia, Metabolic Diseases, Hyperlipidemias, Dyslipidemias, Lipid Metabolism Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PegozaferminDrug
Subcutaneous injection
PlaceboDrug
Subcutaneous injection
| Study group | Role | What they receive |
|---|---|---|
| Pegozafermin - 30mg once a week | Experimental | Not described Receives: Drug: Pegozafermin |
| Pegozafermin - 20mg once a week | Experimental | Not described Receives: Drug: Pegozafermin |
| Placebo once a week | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent change from baseline in fasting TG
Measured: 26 weeks
Secondary outcomes (8)
Percent change from baseline in non-high-density lipoprotein cholesterol (non-HDL-C)
Measured: 26 weeks
Percent change from baseline in high-density lipoprotein cholesterol (HDL-C)
Measured: 26 weeks
Percent change from baseline in very low-density lipoprotein cholesterol (VLDL-C)
Measured: 26 weeks
Percent change from baseline in total cholesterol (TC)
Measured: 26 weeks
Change from baseline in liver fat by magnetic resonance imaging - whole liver proton density fat fraction (MRI-PDFF)
Measured: 26 weeks
Percent change from baseline in apolipoprotein B (apo-B)
Measured: 26 weeks
Change in HbA1c at Week 26 for those with baseline ≥7.0%
Measured: 26 weeks
Percent change from baseline in fasting TG
Measured: 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2023
- Study start15 Jun 2023
- Primary completion7 Jul 2025
- Study completion9 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Severe HypertriglyceridemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 369 participants (actual)
Sponsor and investigators
- Lead sponsor
- 89bio, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Teresa Parli, MD, Study director, 89bio, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05852431
- Sponsor's protocol ID
- BIO89-100-231
- Other IDs
- 2023-503576-25-00, 2023
- Acronym
- ENTRUST
- Status last verified
- Jun 2026
- First submitted
- 2 May 2023
- Last updated
- 7 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study
- ClinicalTrials.gov ID
- NCT05852431
- Acronym / sponsor ID
- ENTRUST / BIO89-100-231
- Conditions
- Severe Hypertriglyceridemia
- Keywords
- SHTG, Hypertriglyceridemia, Metabolic diseases, Hyperlipidemias, Dyslipidemias, Lipid Metabolism Disorders
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 369 participants (actual)
- Lead sponsor
- 89bio, Inc.Industry (pharma, biotech, devices)
- Study start
- 15 Jun 2023 (actual)
- Primary completion
- 7 Jul 2025 (actual)
- Study completion
- 9 Apr 2026 (actual)
- First posted
- 10 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Pegozafermin - 30mg once a week | Experimental | Drug: Pegozafermin |
| Pegozafermin - 20mg once a week | Experimental | Drug: Pegozafermin |
| Placebo once a week | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age ≥22 years
- Willing to enter a medication/lifestyle stabilization period during the screening period, which means maintaining those stable medication, eating, and exercise habits for the duration of the study
- Subjects should be on stable background Lipid Modifying Therapy (LMT) to manage ASCVD for a minimum of 4 weeks prior to first qualifying TG
Key exclusion criteria (8 listed)
- Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
- Uncontrolled or newly diagnosed (≤3 months since diagnosis) Type 2 diabetes mellitus as determined by the Principal Investigator. Subjects must have HbA1c level ≤9.5% at Screening. Medications for glucose management must be stable for at least 4 weeks prior to Screening
- Type 1 diabetes mellitus
- A history of symptomatic gallstone disease, gallstone pancreatitis (unless treated with cholecystectomy), or any other ongoing symptomatic biliary disease
- Acute pancreatitis within 6 months prior to Screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PegozaferminSubcutaneous injection | Drug | Pegozafermin - 20mg once a week, Pegozafermin - 30mg once a week |
| PlaceboSubcutaneous injection | Drug | Placebo once a week |
Primary outcome
Percent change from baseline in fasting TG
Time frame: 26 weeks
8 secondary outcomes
Percent change from baseline in non-high-density lipoprotein cholesterol (non-HDL-C)
Time frame: 26 weeks
Percent change from baseline in high-density lipoprotein cholesterol (HDL-C)
Time frame: 26 weeks
Percent change from baseline in very low-density lipoprotein cholesterol (VLDL-C)
Time frame: 26 weeks
Percent change from baseline in total cholesterol (TC)
Time frame: 26 weeks
Change from baseline in liver fat by magnetic resonance imaging - whole liver proton density fat fraction (MRI-PDFF)
Time frame: 26 weeks
Percent change from baseline in apolipoprotein B (apo-B)
Time frame: 26 weeks
Change in HbA1c at Week 26 for those with baseline ≥7.0%
Time frame: 26 weeks
Percent change from baseline in fasting TG
Time frame: 52 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Severe Hypertriglyceridemia
RecruitingPhase 2
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Severe Hypertriglyceridemia
RecruitingPhase 2
A Study to Assess the Safety, Tolerability and Efficacy of ION775
Hypertriglyceridemia, Severe Hypertriglyceridemia
RecruitingPhase 3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
Severe Hypertriglyceridemia
RecruitingPhase 1
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Cardiovascular, Metabolic Disease
Active, not recruitingPhase 2
Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis
Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Teresa Parli, MD study director
89bio, Inc.
177 sites in 20 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Pegozafermin in people with Severe Hypertriglyceridemia, run by 89bio, Inc. at 177 sites in 20 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 177 sites in United States, Argentina, Bulgaria, Spain, India and 15 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent change from baseline in fasting TG (time frame: 26 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026; AzTrials last refreshed its copy on 8 Nov 2026.